Cargando…

Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma

The present study aimed to evaluate the efficacy of three-year subcutaneous SQ-standardized specific immunotherapy (SCIT) in house dust mite (HDM)-allergic children with asthma. Ninety children with allergic asthma to HDMs, with or without allergic rhinitis, were randomly divided into two groups, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	HUI, YU, LI, LING, QIAN, JUN, GUO, YUN, ZHANG, XILIAN, ZHANG, XIAOJUAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919950/ https://www.ncbi.nlm.nih.gov/pubmed/24520258 http://dx.doi.org/10.3892/etm.2014.1469

Ejemplares similares

SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma
por: Blumberga, G, et al.
Publicado: (2011)

Cost utility analysis of the SQ(®) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting
por: Hahn-Pedersen, J., et al.
Publicado: (2016)

Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases
por: Yang, Yaqi, et al.
Publicado: (2021)

House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
por: Nogami, Kazutaka, et al.
Publicado: (2022)

New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ(®) tablets
por: Vitiello, Gianfranco, et al.
Publicado: (2020)

Oral immunotherapy with the ingestion of house dust mite extract in a murine model of allergic asthma
por: Wang, Yao-Tung, et al.
Publicado: (2018)

Cost-effectiveness of SQ(®) HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany
por: Green, William, et al.
Publicado: (2017)

Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
por: Rieker-Schwienbacher, Juliane, et al.
Publicado: (2013)

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients
por: Chen, Huan, et al.
Publicado: (2022)

Precision Medicine in House Dust Mite-Driven Allergic Asthma
por: Eguiluz-Gracia, Ibon, et al.
Publicado: (2020)

Allergen-specific immunotherapy with Alutard SQ improves allergic inflammation in house-dust mites-induced allergic asthma rats through inactivation of the HMGB1/TLR4/NF-κB pathway
por: Zhai, Yingying, et al.
Publicado: (2023)

Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
por: Rattanamanee, Tipyapa, et al.
Publicado: (2022)

The SQ HDM SLIT‐Tablet is safe and well tolerated in patients with House Dust Mite allergic rhinitis with or without asthma: A “real‐life” French study
por: Demoly, Pascal, et al.
Publicado: (2022)

Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy
por: Aarestrup, Matheus Fonseca, et al.
Publicado: (2021)

A Retrospective Study of Clinical Response Predictors in Subcutaneous Allergen Immunotherapy With House Dust Mites for Allergic Rhinitis
por: Lee, Ji-Ho, et al.
Publicado: (2018)

House dust mite subcutaneous immunotherapy has sustained long‐term effectiveness on allergic rhinitis and asthma: A 10‐year follow‐up
por: Rodriguez‐Plata, Elena, et al.
Publicado: (2023)

Immunotherapy of house dust mite allergy
por: Yang, Lin, et al.
Publicado: (2017)

Efficacy and safety of subcutaneous immunotherapy in asthmatic children allergic to house dust mite: a meta-analysis and systematic review
por: Zheng, Chen, et al.
Publicado: (2023)

Could FeNO Predict Asthma in Patients with House Dust Mites Allergic Rhinitis?
por: Muntean, Ioana Adriana, et al.
Publicado: (2020)

Allergic Rhinitis and House Dust Mite Sensitization Determine Persistence of Asthma in Children
por: Brzozowska, A., et al.
Publicado: (2022)

Outcome of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitive to House Dust Mites
por: Kim, Seon-Tae
Publicado: (2015)

Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
por: Trebuchon, Florence, et al.
Publicado: (2014)

Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis
por: Proctor, Thomas, et al.
Publicado: (2020)

Shrimp sensitization in house dust mite allergic patients
por: Ukleja-Sokołowska, Natalia, et al.
Publicado: (2020)

Altered Sphingolipid Metabolism Is Associated With Asthma Phenotype in House Dust Mite-Allergic Patients
por: Kowal, Krzysztof, et al.
Publicado: (2019)

Insights Into Mucosal Innate Immune Responses in House Dust Mite-Mediated Allergic Asthma
por: Abu Khweek, Arwa, et al.
Publicado: (2020)

Association between serum zonulin level and severity of house dust mite allergic asthma
por: Baioumy, Shereen A., et al.
Publicado: (2021)

Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites
por: Chang, Hyun, et al.
Publicado: (2009)

The Effectiveness of Allergen Immunotherapy in Adult Patients with Atopic Dermatitis Allergic to House Dust Mites
por: Bogacz-Piaseczyńska, Agnieszka, et al.
Publicado: (2022)

Allergen Immunotherapy–Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite–Allergic Asthma Patients
por: Feng, Mulin, et al.
Publicado: (2020)

Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust Mites
por: Kim, Shin Hye, et al.
Publicado: (2015)

Identification of Robust Biomarkers for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With House Dust Mite-Induced Allergic Rhinitis by Multiple Cytokine Profiling
por: Xie, Shaobing, et al.
Publicado: (2022)

Standardization of House Dust Mite Extracts in Korea
por: Jeong, Kyoung Yong, et al.
Publicado: (2012)

Biosignature for airway inflammation in a house dust mite-challenged murine model of allergic asthma
por: Piyadasa, Hadeesha, et al.
Publicado: (2016)

Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite
por: Barberi, Salvatore, et al.
Publicado: (2015)

Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis
por: Kim, Sae-Hoon, et al.
Publicado: (2018)

House dust mite control measures in the treatment of asthma
por: Vallance, Gillian, et al.
Publicado: (2006)

New approaches to immunotherapy in house dust mite allergy
por: Kim, In Sik
Publicado: (2022)

A Real-Life One-Year Non-Interventional Study Assessing Safety, Tolerability, and Treatment Outcome of the SQ HDM SLIT-Tablet (Acarizax(®)) in House Dust Mite Allergic Rhinitis With or Without Asthma
por: Sidenius, Kirsten, et al.
Publicado: (2021)

P79 - AsthmaVent – effect of mechanical ventilation on asthmacontrol in house dust mite allergic children with asthma
por: Viskum Hogaard, Nina
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mvmqdoq3lknndclv7rfk9v0l1j